Controlling inflammation and healing cells could be the key to controlling this eye disease

Uveitis is an inflammation of the uvea, or eye wall—the middle layer of tissue of the eye. Whereas conjunctivitis affects the outer layer of the eye, uveitis affects the interior of the eye in the front, middle, or back of the organ.

There are many different causes of uveitis, and it can lead to glaucoma, cataracts or blindness if left untreated.

Although considered a rare condition, it is the third most common cause of blindness in developed nations and afflicts nearly 2 and a half million people¹ worldwide.

Uveitis can come on suddenly or progressively over time, and cause vision changes ranging from mild to severe vision loss.

Currently, uveitis is primarily treated with anti-inflammatory eyedrops—but AAGP® could hold the key to a more powerful and effective solution.


What causes uveitis

Uveitis can be caused by several factors, and it’s not always easy to determine the culprit. Many times, the inflammation is due to an autoimmune condition or systemic inflammation, such as that created by rheumatoid arthritis. It can be spurred by an infection such as shingles or toxoplasmosis. It can even be brought about by an injury to the eye.

In some cases, doctors cannot identify the underlying cause of uveitis.

Uveitis symptoms

One of the most visible signs of uveitis is redness of the eye. Other symptoms can include:

  • Eye pain
  • Vision impairment
  • Light sensitivity
  • Seeing floating specks or spots
  • Blurry vision
Microscope image

Treatment for uveitis

Uveitis is often treated with anti-inflammatory eye medications such as corticosteroids. These medications may be administered via eye drops, injections, or tablets taken by mouth. Eye drops that widen or dilate the pupil may also give relief.

If uveitis is determined to be caused by an underlying infection, the doctor may treat it with antibiotics or antivirals.

If the root cause is an inflammatory immune response, then immunosuppressants may be called into play. However, the side effects from these medications may mean that they’re only used if the uveitis severely threatens vision.

AAGP® as a potential solution

Side effects and suboptimal outcomes have created the need for more effective solutions — and that’s where AAGP® comes in. Thanks to the unique protection this proprietary glycopeptide offers to inflamed cells, eye treatments containing AAGP® could reduce inflammation and provide relief from uveitis. AAGP® has been shown to improve cell survivability and functionality, both which could yield a pathway to healing disease.

ProtoKinetix research and clinical trials

Our research has yielded exciting results in ophthalmic care, showing promise in the treatment of oculuar inflammation.

See our research pipeline to review the status of our active research as we explore new solutions.

Market potential for uveitis

Globally, the market potential for uveitis treatments is projected to reach nearly $700 million by 2026, with a CAGR of 4.6%² to 5.8%. With the rising incidence of uveitis, demand for treatment will rise too.

2018 Market Revenuet:

$478 Million

2026 Market Forecast:

$687 Million


You can support our research into uveitis treatments while supporting your own financial future. To learn about potential research options, contact your broker or reach out to the ProtoKinetix team.

  • This field is for validation purposes and should be left unchanged.